Indeed, a tracer for α-synuclein would not only help to differentiate idiopathic PD from atypical PD and different forms of atypical PD from each other but may also allow monitoring of target engagement in future therapies for α-synucleinopathies. Here, SNCA is linked to synucleinopathy.